Cagrilintide appears to impact feeding reward-systems, making it useful for exploring binge-pattern behaviors or compulsive-eating models in laboratory research
Another key point: stopping therapy leads to regain in most people, which argues for getting to and staying at an effective maintenance dose rather than hovering at subtherapeutic levels
Si quieres saber ms sobre salud Diabticos: qu es la diabetes, tipos y alimentacin Radicales Libres y Estrs Oxidativo Comienza tu rutina de hbitos saludables y vida sana, por dnde empezar
Future research should focus on defining biomarkers that reflect flux proportionality and redox reserve in patients undergoing GLP-1RA therapy
In a Mayo Clinic study presented at an annual meeting of the Endocrine Society in July 2025, researchers found that, over 18 months, 40 postmenopausal women who combined the GLP-1 drug tirzepatide (used in Mounjaro and Zepbound) with hormone therapy lost an average of 17 percent of their body weight